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Abstract
Background: The indications for warfarin treatment in primary health care are increasing. An
undertreatment with warfarin is reported in the prevention of embolic stroke in patients with
chronic atrial fibrillation, and can be suspected for other indications. Information on the prevalence
and incidence of diseases treated with warfarin would reveal useful data for audits concerning
management of anticoagulant treatment. We aimed to assess warfarin treatment in primary health
care with regard to prevalence, incidence, treatment diagnosis and patient characteristics.
Methods: A one-year retrospective study of electronic patient records up to May 2000 in primary
health care in Stockholm, Sweden. Five primary health care centres with a registered population of
75 146. Main outcome measures were prevalence, incidence and treatment diagnosis.
Results: Five hundred and seven patients, mean age 71.9 years, were on warfarin treatment. The
prevalence was 0.67% (age-adjusted 0.75%), and it was significantly higher for men (0.78%) than for
women (0.58%) (p = 0.01). In the age group 75–84 years the prevalence was 4.54%. The most
prevalent treatment diagnosis was chronic atrial fibrillation (0.28%), which was more predominant
for males (p = 0.02), followed by cerebrovascular disease (0.13%) and deep venous thrombosis
(0.13%). The yearly incidence of warfarin treatment was 0.17%, with chronic atrial fibrillation as the
predominant treatment diagnosis.
Conclusion: Warfarin treatment in primary health care is prevalent among the elderly. Chronic
atrial fibrillation is the main treatment diagnosis. There is a gender difference favouring men in
general and chronic atrial fibrillation as the treatment diagnosis.
Background
Oral anticoagulant drugs, i.e. vitamin K antagonists, have
been shown in well-designed clinical trials to have anti-
thrombotic effectiveness in a variety of disorders and con-
ditions. They are effective in the prevention of venous
thromboembolism, thrombosis on heart valve prostheses,
embolic stroke in patients with chronic atrial fibrillation
(CAF) and cerebrovascular disease [1], in patients with
pulmonary embolism [2], and as secondary prophylaxis
after myocardial infarction [3]. Warfarin is the standard
oral anticoagulant drug used in Sweden.
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The indications for warfarin treatment in primary health
care (PHC) are increasing [4,5]. It is well known that effi-
cacy in clinical trials may be a poor guide to effectiveness
in everyday clinical practice, and undertreatment with
warfarin is reported for CAF [6], and can be suspected for
other indications. Information on the occurrence (i.e.
prevalence and incidence) of these diseases would reveal
useful data for audits concerning management of antico-
agulant treatment. The prevalence of warfarin treatment
differed somewhat in earlier studies. In a Swedish study a
prevalence of 0.52% was reported [7]. Several studies re-
veal that CAF is the most common treatment diagnosis
[5,8]. However, these studies have not documented anti-
coagulation management in a representative sample of
clinics. There is thus a need for generalisable data relating
to warfarin treatment in everyday clinical practice in order
to estimate and discuss the quantity and quality of warfa-
rin treatment in PHC.
Warfarin has a narrow therapeutic range and requires fre-
quent monitoring and dosage adjustment. The workload
involved in anticoagulant treatment has grown [9,10],
and monitoring is increasingly managed by general prac-
titioners (GP) [7,11]. It is well known that the number of
bleeding and thromboembolic complications during
treatment with oral anticoagulants is dependent on the in-
dications for treatment.
Patients on warfarin treatment in Stockholm are now al-
most exclusively managed in PHC. Use of electronic pa-
tient records is presently almost universal among GPs in
the area, providing us with clinical data that is useful for
audits and research. A population registry is maintained
for each GP, which makes it possible to calculate the total
registered population for the PHC centres.
The objective of this study was to study warfarin treatment
in everyday clinical practice in PHC with regard to preva-
lence, incidence, treatment diagnosis, and patient
characteristics.
Methods
Selection of PHC centres
In order to get a representative sample, we invited five
PHC centres from five different health care districts in
Stockholm County, and all agreed to participate. In each
PHC centre one GP was appointed as investigator. Each
investigator retrieved information on all patients attend-
ing the PHC centre in question, regardless of who the re-
sponsible GP was. The total registered population
(calculated from a population registry maintained for
each GP) of the participating GPs comprised 75 145 indi-
viduals at the end of the study period.
Selection of patients
The initial selection criterion included all patients on war-
farin treatment during the 12-month study period (June
1999 up to May 2000). Eligible patients were further de-
fined as patients who were monitored using pro-
thrombin-time and whose daily dosages of warfarin were
prescribed by a GP at the PHC centre. The electronic pa-
tient record systems were identified through their statisti-
cal modules in a primary data retrieval including age and
gender. The investigator thereafter manually reviewed all
these records.
Patients who had received a minimum of 30 consecutive
days of treatment during the study period were included.
In other words, patients on treatment at the start of the
study period, patients starting treatment during the study
period, and patients discontinuing treatment during the
study period were included. All patients on treatment, as
defined above, were considered eligible. The clearly and
unambiguously determinable current indication or indi-
cations for treatment were listed for each patient.
Statistical analysis
The data were analysed using SPSS® software. Independ-
ent two-sample t-tests were used to compare interval
scaled variables. The Chi-square test was used to test dis-
tribution of cross-classified nominal variables. Ninety-five
percent confidence intervals (CI) were used.
Ethical considerations
This study was approved by the regional ethics committee
at Karolinska Insitutet.
Results
Out of the registered population, 507 patients were on
warfarin treatment. The mean age of these patients was
71.9 years, with a higher mean age of 74.7 for women and
a mean age of 69.6 for men (p = 0.002). The age distribu-
tion is shown in Table 1. There was a statistically signifi-
cant predominance of men overall (p = 0.01) as well as in
the age group 45–64 years (p < 0.01), whereas women
were predominant in the age group 85+ (p < 0.01).
The overall prevalence for warfarin treatment was 0.67%
(Table 1), with 0.78% in men and 0.58% in women. On
standardizing by sex and age with regards to the whole
Swedish population (in December 1999), this would give
a prevalence of 0.75% (0.89% for men and 0.63% for
women). The age group 75–84 years had the highest prev-
alence, which was 4.54%. The most common treatment
diagnosis was CAF (0.28%), followed by cerebrovascular
disease (0.13%), deep venous thrombosis (0.13%) and
prosthetic valve (0.12%). Men had CAF as a treatment di-
agnosis more frequently than women (p = 0.02). TheBMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/3
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mean age in different groups of treatment diagnoses
ranged from 69.4 years for deep venous thrombosis to
80.8 years for peripheral artery disease.
The number of patients who started treatment with warfa-
rin (and continued for more than 90 days) at the partici-
pating PHC centres was 127, giving a yearly incidence of
0.17%. The treatment diagnosis with the highest inci-
dence was CAF (0.07%) (Table 2).
Discussion
In this study we investigated warfarin treatment in PHC
with the main focus on its occurrence and treatment diag-
nosis. We found it to be fairly common among the elderly,
with a gender difference favouring males and dominated
by CAF.
The prevalence and incidence for all treatment diagnoses
of warfarin treatment in a registered population have re-
ceived little attention, and differs somewhat in similar
studies. In a Swedish study in 1997, an age-adjusted prev-
alence of 0.88% (1.19% for men and 0.58% for women)
was reported [7]. The figures in our study (0.67%, age-ad-
justed 0.75%) were in line with that study, indicating that
there is no increase. However, in a Finnish PHC study the
reported age-adjusted prevalence was 0.65% [8]. There
does not appear to be a pronounced increase, but as GPs
are encouraged to consider warfarin treatment more fre-
quently due to its suboptimal use, some increase would
be expected. Maximising adherence with the guidelines
on anticoagulant treatment seems to be increasingly im-
portant to primary care providers. Numerous constraints
probably influence this, such as organisational problems,
reimbursement issues, as well as issues related to the GPs
and the patients.
The gender difference in our study was also found in a
similar study [7], but in Finnish PHC no difference was
found [8]. This could be explained by the higher ages of
the females and a different distribution of treatment diag-
noses, but it could also reveal a real gender bias regarding
adherence to guidelines. Such gender differences are
Table 1: Patients on warfarin treatment in a registered population of 75146. Age and gender distribution and prevalence, presented as 
number of patients, percentage of patients, percentage of women and 95% confidence intervals (CI).
Age and gender group 
(years and gender)
Number of patients Percentages of patients (%) 
(n = 507)
Prevalence (%) Percentage of women (%) 
(CI)
0–44 17 3.4 0.04 35 (10; 61)
45–64 99 19.5 0.53 26 (17; 35)1
65–74 143 28.2 2.80 44 (36; 52)
75–84 203 40.0 4.54 49 (42; 56)
85+ 45 8.9 2.62 67 (52; 81)2
All ages 507 100.0 0.67 44 (40; 49)3
Men 282 55.6 0.78
Women 225 44.4 0.58
1 significantly more men (p < 0.01);2 significantly more women (p < 0.01);3 significantly more men (p = 0.01)
Table 2: Patients on warfarin treatment in a registered population of 75146. Treatment diagnosis, prevalence and incidence, presented 
as number of patients and percentage.
Treatment diagnosis Number of 
patients (n)
Mean age Percentage of 
women (%)
Percentage of the study 
group (%) (n = 507)
Prevalence (%) Incidence (%)
Chronic atrial fibrillation 211 73.8 42.2 2 41.6 0.28 0.07
Cerebrovascular disease 96 74.5 47.9 18.9 0.13 0.02
Deep venous thrombosis 96 69.4 42.1 18.9 0.13 0.05
Prosthetic valve 89 70.1 42.7 17.6 0.12 0.01
Pulmonary embolism 65 72.4 53.9 12.8 0.09 0.01
Peripheral artery disease 14 80.8 50.0 2.8 0.02 0
Cardiac infarction 10 75.4 60.0 2.0 0.01 0.01
Other indications 31 71.6 45.2 6.1 0.04 0
Any diagnosis (all patients) 507 1 71.9 44.4 100 1 0.67 0.17
1 not a sum, as 105 patients had more than one treatment diagnosis 2 significantly more men (p = 0.02) 3 significantly more men (p = 0.01)BMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/3
Page 4 of 4
(page number not for citation purposes)
found in the management of other diseases such as chron-
ic heart failure [12].
Prevalence figures are often not based on a registered pop-
ulation, as in our study, but rather on the population in a
geographical area, and this constitutes an advantage of
our study. Further, most studies on anticoagulant treat-
ment are not based on PHC, with a representative sample
of patients from everyday clinical practice. There is no rea-
son to believe that patients on warfarin treatment were
missed, since all patients on treatment (as defined above)
at the PHC centres are registered under prothrombin-time
values in the laboratory module of the record systems.
However, there are probably a few patients on warfarin
treatment who have never been in contact with a GP, and
the prevalence may have been underestimated.
The indications for warfarin treatment in PHC were in line
with those in some similar studies [4,5], but the figures for
CAF were somewhat higher in our study. The treatment
diagnosis, in terms of the reason for treatment, can be dis-
cussed, as a large proportion of the patients have more
than one, and selecting one of several diagnoses as the
main treatment diagnosis can be questionable. The high
figure for CAF in our study is due in part to the fact that it
is frequently a concurrent treatment diagnosis.
Further research is needed on the management of all pa-
tients with diseases with indications for anticoagulant
treatment regarding pharmacological treatment and other
clinical information. For example, it would also be of in-
terest to study non-warfarin treated patients with CAF.
However, this would require reliable ways of identifying
these patient groups in the electronic patient record
systems.
Given the frequent monitoring and dosage adjustments,
there is a significant workload in warfarin treatment in
PHC in Sweden. An increasing number of patients in the
Stockholm area have already been referred to PHC, as has
been suggested [6]. A future increase can nevertheless be
expected, and this may require an organised approach to
anticoagulant management including computer dosing
systems and improved systems for follow-up.
Conclusions
Warfarin treatment in PHC is common among the elderly.
CAF is most common treatment diagnosis. There is a gen-
der difference favouring men in general and CAF as the
treatment diagnosis.
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